The Lipid Hydrolase ABHD6 is a Therapeutic Target in Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)-Related Hepatocellular Carcinoma
Danny Orabi, William J. Massey, Kevin K. Fung, Venkateshwari Varadharajan, Iyappan Ramachandiran, Rakhee Banerjee, Daniel J. Silver, Lucas J. Osborn, Amanda L. Brown, Stephanie Marshall, Daniel Ferguson, Shijie Cao, Rebecca C. Schugar, Chelsea Finney, Chase K. A. Neumann, , J. Mark Brown
This study identifies ABHD6 as a therapeutic target in MASLD-related HCC by showing its role in lysosomal lipid remodeling and tumor progression.
bioRxiv · Jul 29, 2025 · PreprintCancer Biology